Navigation Links
Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
Date:2/19/2009

MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation. The results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009. The I2 Summit is part of the Annual Meeting of the American College of Cardiology (ACC) being held March 28 - 31 in Orlando, Florida.

"This is a very important clinical study comparing the WATCHMAN to warfarin in the management of patients with atrial fibrillation. We are looking forward to the presentation by Dr. David Holmes, the Principal Investigator of the PROTECT AF Trial, at the ACC," remarked Jim Bullock, President and CEO. Hand-on demonstrations of the WATCHMAN technology will be available at the Atritech booth # 2857.

In August of 2008, Atritech announced the filing of its Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA). The PMA contained the results of the PROTECT AF Clinical Trial which began enrollment in early 2005. The WATCHMAN Device continues to be implanted in a limited number of sites while the product is under review at the FDA. To date over 70 devices have been implanted in the Continued Access Registry.

Atritech's WATCHMAN LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke due to embolization of clots that may form in the LAA. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions and increases the risk of bleeding. The WATCHMAN device may be an effective alternative to warfarin for these patients.

About Atritech

Atritech is privately held and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The Vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net.


'/>"/>
SOURCE Atritech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Atritech Announces Completion of a $22 Million Equity Financing
2. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
3. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
4. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
5. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
6. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
7. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care Management ... new PhRMA report on patient out-of-pocket spending: ... and Medicaid Services (CMS), the average amount spent out-of-pocket ... of drug spending in 2016, down from 23% in ... pricing problem, not a coverage problem. Health plans don,t ...
(Date:3/29/2017)...  NuVasive, Inc. (NASDAQ: NUVA), a leading medical ... minimally disruptive, procedurally-integrated solutions, today announced U.S. Food ... CoRoent® Small Interbody™ System indicated for intervertebral body ... spine. This marks the first U.S. clearance for ... to four contiguous levels. Cervical radiculopathy ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor ... "The rubber bands used in conjunction with my braces always rubbed against the ... a way to prevent this problem." The O.B.S. was the result of his ...
Breaking Medicine News(10 mins):